TCD-717 is the Company's leading product. This first-in-class, precisely-targeted ChoKα inhibitor is a small molecule that has demonstrated its effectiveness in treating various cancer types in pre-clinical studies.

TCD-717 is currently being evaluated in a Phase I clinical trial as a treatment for solid tumors. The study has been approved by the FDA as part of an Investigational New Drug (IND) application, and is being conducted in two medical centers in the U.S

With FDA approval TCD joins an exclusive club of a handful of Spanish companies that have received the FDA's approval for a first-in-man study, meeting the high requirement level of the agency.

The cumulative market potential in Europe and the US for TCD-717 is over 880,000 new patients a year in various indications, with sales expected to be in the billions.

All rights reserved. 2011 TCD Pharma                                         Legal Statement                                                          Designed by Freeman y la luz